# The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines

> **NCT05364580** · PHASE3 · COMPLETED · sponsor: **Protox Inc.** · enrollment: 269 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** PROTOXIN
- **BIOLOGICAL:** Botox®

## Key facts

- **NCT ID:** NCT05364580
- **Lead sponsor:** Protox Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-06
- **Primary completion:** 2023-06-20
- **Final completion:** 2023-10-06
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05364580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05364580, "The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05364580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*